GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » The Cooper Companies Inc (NAS:COO) » Definitions » Debt-to-EBITDA

COO (The Cooper) Debt-to-EBITDA : 2.25 (As of Oct. 2024)


View and export this data going back to 1983. Start your Free Trial

What is The Cooper Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

The Cooper's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2024 was $33 Mil. The Cooper's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2024 was $2,550 Mil. The Cooper's annualized EBITDA for the quarter that ended in Oct. 2024 was $1,146 Mil. The Cooper's annualized Debt-to-EBITDA for the quarter that ended in Oct. 2024 was 2.25.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for The Cooper's Debt-to-EBITDA or its related term are showing as below:

COO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.8   Med: 2.73   Max: 3.5
Current: 2.41

During the past 13 years, the highest Debt-to-EBITDA Ratio of The Cooper was 3.50. The lowest was 1.80. And the median was 2.73.

COO's Debt-to-EBITDA is ranked worse than
64.04% of 431 companies
in the Medical Devices & Instruments industry
Industry Median: 1.54 vs COO: 2.41

The Cooper Debt-to-EBITDA Historical Data

The historical data trend for The Cooper's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Cooper Debt-to-EBITDA Chart

The Cooper Annual Data
Trend Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.50 1.80 3.15 2.90 2.41

The Cooper Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.85 2.81 2.64 2.34 2.25

Competitive Comparison of The Cooper's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, The Cooper's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Cooper's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where The Cooper's Debt-to-EBITDA falls into.



The Cooper Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

The Cooper's Debt-to-EBITDA for the fiscal year that ended in Oct. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(33.3 + 2550.4) / 1071.7
=2.41

The Cooper's annualized Debt-to-EBITDA for the quarter that ended in Oct. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(33.3 + 2550.4) / 1146.4
=2.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Oct. 2024) EBITDA data.


The Cooper  (NAS:COO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


The Cooper Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of The Cooper's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


The Cooper Business Description

Address
6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, USA, 94583
CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.
Executives
White Albert G Iii officer: VP & Treasurer 6790, SPRINGDALE COURT, VICTOR NY 14564
Agostino Ricupati officer: Sr. VP, Finance & Tax C/O THE COOPER COMPANIES, INC., 6140 STONERIDGE MALL ROAD, SUITE 590, PLEASANTON CA 94588
Brian G Andrews officer: Treasurer 4300A 17TH STREET, SAN FRANCISCO CA 94114
Daniel G Mcbride officer: VP and Senior Counsel 5 EL CORTE, ORINDA CA 94563
Robert S Weiss director, officer: EVP and CFO 6140 STANERIDGE MALL RES #590, PLEASSANTON CA 94503
Gary S Petersmeyer director 3400 CENTRAL AVENUE, SANTA CLARA CA 95051
Warner Gerard H Iii officer: President, CooperVision, Inc. C/O COOPER COMPANIES INC., 6101 BOLLINGER CANYON ROAD, SUITE 500, SAN RAMON CA 94583
Jody S Lindell director 2536 FILLMORE ST., SAN FRANCISCO CA 94115
Cynthia L Lucchese director 7966 N. ILLINOIS STREET, INDIANAPOLIS IN 46260
Nicholas Khadder officer: VP, General Counsel & Corp Sec 2836 JOHNSON AVENUE, ALAMEDA CA 94501
Maria Rivas director C/O MEDIDATA SOLUTIONS, INC., 350 HUDSON STREET, 9TH FLOOR, NEW YORK NY 10014
Teresa S Madden director 414 NICOLLET MALL, MINNEAPOLIS MN 55401
Robert D Auerbach officer: President, CSI C/O THE COOPER COMPANIES, INC., SUITE 590, PLEASANTON CA 94588
Holly R Sheffield officer: EVP, CSO C/O THE COOPER COMPANIES, INC., 6140 STONERIDGE MALL ROAD, SUITE 590, PLEASANTON CA 94588
Mark J Drury officer: VP, General Counsel & Sec. C/O COOPERCOMPANIES, 6101 BOLLINGER CANYON ROAD, SUITE 500, SAN RAMON CA 94583